AXOGEN, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.87 USD | +0.69% |
|
-10.52% | -14.06% |
| May. 02 | Transcript : AxoGen, Inc., Q1 2024 Earnings Call, May 02, 2024 | |
| May. 02 | Earnings Flash (AXGN) AXOGEN Posts Q1 Revenue $41.4M, vs. Street Est of $42.1M | MT |
Presentation Operator MessageOperator (Operator)Good day, and welcome to the AxoGen, Inc. 2021...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its products include Avance nerve graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Axotouch Two-Point Discriminator and Axoguard HA+ Nerve Protector. Avance nerve graft is a biologically active processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site. Axoguard Nerve Connector is a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce nerve reconstruction while preventing soft tissue attachment. Axotouch Two-Point Discriminator is used to measure the innervation density of any surface area of the skin.
Calendar
2024-06-05
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.87
USD
Average target price
13.4
USD
Spread / Average Target
+128.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.06% | 257M | |
| +8.07% | 219B | |
| +7.87% | 185B | |
| +12.75% | 135B | |
| +25.79% | 107B | |
| +11.59% | 51.28B | |
| +4.88% | 51.01B | |
| +2.71% | 41.85B | |
| +4.90% | 37.02B | |
| +23.75% | 31.27B |
- Stock Market
- Equities
- AXGN Stock
- News AxoGen, Inc.
- Transcript : AxoGen, Inc. - Shareholder/Analyst Call